Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
07/2003
07/03/2003US20030125537 Neovascularization; platelet derived growth factors; vascular permeability factors; wound healing agents; antitumor/antiproliferative agents; antisense agents; for treatment of intestinal malabsorption syndrome
07/03/2003US20030125536 Fusion proteins/antigen presenting cells for promoting expansion of lymphocytes; vaccines
07/03/2003US20030125535 Secreted and transmembrane polypeptides and nucleic acids encoding the same
07/03/2003US20030125533 Regulation of human sphingosine kinase-like protein
07/03/2003US20030125524 Fusion proteins; interleukins; colony stimulating factors; cellular proliferation/differentiation; culturing bone marrow or peripheral blood cells; natural killer cells
07/03/2003US20030125523 Novel neuropilin/growth factor complexes and uses thereof
07/03/2003US20030125521 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
07/03/2003US20030125520 Novel hemopoietin receptor protein, NR10
07/03/2003US20030125519 Ligand for the c-kit receptor and methods of use thereof
07/03/2003US20030125515 Endcapped genetically engineered human immunodeficiency viral polypeptides; viricides
07/03/2003US20030125509 Indomethacin entrapped within polysaccaride (dextran) or proteins
07/03/2003US20030125372 In which resistance results from conversion of an amide bond to an ester bond in cell wall peptide precursors of bacteria which comprises using an antibacterial amount of vancomycin and an agent effective to selectively cleave ester bond
07/03/2003US20030125338 Compounds, compositions and methods for modulating beta-amyloid production
07/03/2003US20030125324 Alpha 4 beta 1 integrin and CD49d/ CD29 (vla-4); antiinflammatory agents
07/03/2003US20030125311 Steroid hormones and nontoxic compounds, e.g., Taxol (able to cross the blood-brain barrier) replace pregnenolone bound to microtubule-associated proteins to aid in assembling and stabilizing of microtubules; nervous, glandular disorders
07/03/2003US20030125296 Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
07/03/2003US20030125295 Novel nucleic acid and amino acid sequences
07/03/2003US20030125294 Selective toxin expression in angiogenic endothelial cells
07/03/2003US20030125291 A stabilizer for antisense oligonucleotides, enhancing nuclease stability of enzymatic nucleic acid molecules
07/03/2003US20030125289 Noonan syndrome gene
07/03/2003US20030125288 PI3K - regulatory subunit homology
07/03/2003US20030125287 Antisense oligonucleotides and methods to induce tumor cell death
07/03/2003US20030125286 Transcriptional silencer protein NRF
07/03/2003US20030125281 Compositions and processes using siRNA, amphipathic compounds and polycations
07/03/2003US20030125280 Tissue specific and target RNA-specific ribozymes as antimicrobial therapeutics against microbial pathogens
07/03/2003US20030125278 Immunization of animals by topical applications of a salmonella-based vector
07/03/2003US20030125277 Antisense modulation of activating transcription factor 3 expression
07/03/2003US20030125276 Antisense modulation of thyroid hormone receptor interactor 6 expression
07/03/2003US20030125275 Antisense modulation of hematopoietic cell protein tyrosine kinase expression
07/03/2003US20030125274 Gene expression inhibition, treating brain disorders such as Alzheimer's disease, Down syndrome, schizophrenia, nervous system disorders
07/03/2003US20030125273 Antisense modulation of MHC class II transactivator expression
07/03/2003US20030125272 Gene expression inhibition by antisense oligonucleotides or polynucleotides; immunology
07/03/2003US20030125271 Antisense modulation of vitamin D nuclear receptor expression
07/03/2003US20030125270 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
07/03/2003US20030125262 Methods and reagents for regulation of cellular responses in biological systems
07/03/2003US20030125261 Administering to the mammal a therapeutically acceptable amount of a penta or hexapeptide compound to inhibit the angiogenesis
07/03/2003US20030125260 Administering to the mammal a therapeutically acceptable amount of a tetra or pentapeptide compound to inhibit the angiogenesis
07/03/2003US20030125259 Administering to the mammal a therapeutically acceptable amount of a octa or nonapeptide compound to inhibit the angiogenesis
07/03/2003US20030125258 Bone polypeptide-1
07/03/2003US20030125257 A olilgopeptide or polypeptide containing Leustatin, Chastatin or Tyrstatin
07/03/2003US20030125256 Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
07/03/2003US20030125255 Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
07/03/2003US20030125253 Novel protein, process for producing the same and use therof
07/03/2003US20030125252 Administering to a vertebrate an effective osteogenesis stimulating amount of an RAR (retinoic acid receptor) antagonist to treat both metabolic or non-metabolic diseases; RAR antisense oligonucleotide
07/03/2003US20030125251 Administering a soluble transforming growth factor beta antagonist SR2F to a patient having a tumor, under conditions such that the normal functions of TGF-beta are not detrimentally affected by TGF-beta for metastasis suppression
07/03/2003US20030125250 Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
07/03/2003US20030125249 Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
07/03/2003US20030125248 Novel bone mineralization proteins, DNA, vectors expression systems
07/03/2003US20030125247 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein
07/03/2003US20030125246 Respiratory system related polynucleotides and the polypeptides encoded by these polynucleotides known as respiratory system antigens useful for detecting cancer or cancer metastases of respiratory system tissues
07/03/2003US20030125245 Compositions and methods for therapy and diagnosis of lung cancer
07/03/2003US20030125244 Endoparasiticidal agents
07/03/2003US20030125242 Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
07/03/2003US20030125241 Oligonucleotides for treatment of infectious diseases and disorders caused by viruses, bacteria, protozoa or fungi. Administration of an LNA-modified oligonucleotide modulates expression of a targeted gene associated with the replication
07/03/2003US20030125240 Cyclic peptide antifungal agents
07/03/2003US20030125238 Hemoglobin-based oxygen carriers are prepared by reacting hemoglobin with oxidatively ring-opened polysaccharides such as hydroxyethyl starch or dextran, and storing the resultant conjugate under conditions which allow it to transform to a
07/03/2003US20030125237 Controlled release preparation of insulin and its method
07/03/2003US20030125236 Phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the
07/03/2003US20030125233 Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling
07/03/2003US20030125232 Stabilized proteins with engineered disulfide bonds
07/03/2003US20030125231 Identification of agents useful in the treatment of such diseases based upon the agent's effect on reducing Pim-2 expression. Polypeptides and genetic engineering
07/03/2003US20030125230 Compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation
07/03/2003US20030124741 Serine substituted gold inserted apoferritin; transport proteins; for use in producing semiconductors
07/03/2003US20030124723 Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
07/03/2003US20030124704 Neuroprotectants; inhibition of axonal growth; antitumor agents
07/03/2003US20030124678 Interleukin-2 mutants with reduced toxicity
07/03/2003US20030124677 Amino-terminally truncated MCP-2 as chemokine antagonists
07/03/2003US20030124675 Isolated CDNA encoding tumor necrosis factor binding protein II, its purification, and vectors, hosts and processes using such cDNA
07/03/2003US20030124671 Somatomedins; kringle domains; antitumor agents; antiproliferative agents
07/03/2003US20030124670 Analgesics; antinociceptive agents; antiinflammatory agents; antidiabbetic agents; diagnosing pain disorders
07/03/2003US20030124669 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
07/03/2003US20030124660 Bak promoter expression system
07/03/2003US20030124657 Polyvalent cation-sensing receptor in atlantic salmon
07/03/2003US20030124655 Receptor protein specifically recognizing bacterial dna
07/03/2003US20030124653 Preparing preferential enzymatic polypeptide; lysosomal hydrolases; phosphotransferases; lysosomal storage disease; translation inhibit; enzyme replacement therapy
07/03/2003US20030124649 Membrane associated proteins
07/03/2003US20030124627 Diagnostic and therapeutic compositions and methods related to chemokine (C motif ) XC receptor 1 (CCXCR1), a G protein-coupled receptor (GPCR)
07/03/2003US20030124625 Novel interleukin-1 receptor intracellular ligand proteins and inhibitors of ligand binding
07/03/2003US20030124620 Mullerian inhibiting substance levels and ovarian response
07/03/2003US20030124614 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
07/03/2003US20030124602 Tumour suppresor and uses thereof
07/03/2003US20030124596 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
07/03/2003US20030124593 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
07/03/2003US20030124585 Peptide comprising a portion of exon; use in contraception
07/03/2003US20030124575 Dendritic cells; antigen presenting cells; g-protein coupled receptors; immunotherapy; antiinflammatory agents; antitumor agents; viricides; drug screening
07/03/2003US20030124573 Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
07/03/2003US20030124568 Rectifying potassium channels (kirs); neuroprotectants; ribozymes; antisense therapy; gene therapy
07/03/2003US20030124557 Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
07/03/2003US20030124554 Screening method for compounds capable of modularing egr-1-regulated expression
07/03/2003US20030124553 Skin treatment
07/03/2003US20030124551 Agents implicated in endometriosis
07/03/2003US20030124543 Tumor diagnosis; anticarcinogenic agents; animal models
07/03/2003US20030124531 Secreted and transmembrane polypeptides and nucleic acids encoding the same
07/03/2003US20030124529 Pregnancy-associated plasma protein-A2 (PAPP-A2)
07/03/2003US20030124513 RNA interfering molecule which modulates gene expression; human immunodeficiency virus (HIV); configurations; cleavage
07/03/2003US20030124510 Protein whose genome contains a region which is homologous to DNA restriction enzyme present in plasmid of escherichia coli; immunologically reactive; use in diagnostics and vaccines
07/03/2003US20030124503 Sodium chloride, potassium chloride, glucose, insulin, calcium chloride, lidocaine; pyruvic acid or salt thereof; myocardial ischemia; protects in period of cardiac arrest
07/03/2003US20030124230 Methods and products for bad breath
07/03/2003US20030124222 Oilseed processing
07/03/2003US20030124198 Nutritional or therapeutic supplement and method
1 ... 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 ... 3163